Collaborative Opportunities with the DCCT/EDIC Study
The Diabetes Control
and Complications Trial (DCCT) /
Epidemiology of Diabetes Interventions and Complications (EDIC) Study
is entering its 21st year. From 1983 to 1989, the DCCT recruited 1441 type 1 diabetic
participants. They were randomly assigned to 2 treatment groups, intensive and conventional
for an average of 6.5 years of randomized treatment time. The DCCT ended in 1993
after demonstrating conclusively that intensive treatment (mean HbA1c 7.2 percent)
reduced the development and progression of diabetic retinopathy, nephropathy and
neuropathy, compared to conventional treatment (mean HbA1c 9.0 percent).
In 1994, 96 percent of the living participants enrolled in EDIC for regular observational
follow-up of metabolic and complications status, using similar methods as in the
DCCT. Diabetes care is obtained from the EDIC participants' own physicians, the
HbA1c levels of the former intensive and conventional treatment groups quickly drew
together and have averaged 8.1 percent and 8.2 percent respectively during 9 years
of EDIC follow-up. Nonetheless, the former intensive treatment group continues to
exhibit the same reduction in the risks of diabetic retinopathy, nephropathy and
neuropathy, starting from a new baseline status at the beginning of EDIC. A similar
benefit of intensive treatment during the DCCT on 2 surrogate measures of CVD, carotid
intimal-medial thickness and coronary calcification, first measured during EDIC,
has also been revealed. This carry-over effect of prior glycemic exposure on the
later course of complications (superimposed on the effect of concurrent glycemic
exposure) has been called "metabolic memory" or "metabolic imprinting".
Thus the entire DCCT-EDIC database obtained from type 1 diabetic patients, currently
of average age 43 years and diabetes duration 21 years, consists of frequent regular
assessments of HbA1c, lipid levels, blood pressure and numerous other proven and
putative risk factors for microvascular, neuropathic and macrovascular complications,
as well as frequent regular assessment of the complications themselves. In addition,
serum and urine samples have been obtained annually since the DCCT baseline and
stored frozen at -70° C.
The DCCT/EDIC research group welcomes proposals for collaborative studies from any
investigator who believes he/she has a research idea that could utilize some of
the stored sample collection and clinical phenotypic data in an ancillary study.
The primary objective would be to increase our insight into the pathogenesis of
diabetic complications and/or the mechanism of "metabolic memory" or "imprinting"that
has been uncovered. The scientific questions to be asked, the specific hypotheses
to be tested, the laboratory methods to be employed, and the forms of data analysis
will all be jointly developed by the proposing investigator and the DCCT/EDIC research
group. Any proposal would receive initial review by the relevant DCCT/EDIC committees.
If deemed necessary, independent external scientific review may be arranged by the
NIDDK, in addition to any required scientific review by other funding agencies.
After completion of the new measurements, the data will be sent to the DCCT/EDIC
data coordinating center, where the previously agreed upon analyses and any other
pertinent data analyses will be carried out. Responsibility for presentation, publication
and authorship will be determined according to written DCCT/EDIC policies, available
on request.
Investigators interested in collaborating with the DCCT/EDIC research group should
contact Saul Genuth, chairman of EDIC (phone 216-368-5032, fax 216-368-1485. e-mail
smg15@po.cwru.edu), David Nathan, cochairman of EDIC (phone 617-726-2875, fax 617-726-6781,
e-mail dnathan@partners.org) or Patricia
Cleary, data master of EDIC (phone 301-881-9260, fax 301-881-4471, e-mail
cleary@biostat.bsc.gwu.edu).
Investigators may also request access to DCCT/EDIC samples together with phenotypic
data already in the public domain (DCCT but not EDIC data is available). We expect
to publish a Notice in the NIH guide in Spring 2004 alerting investigators of the
availability of the samples. An example of an earlier notice is available at
www.nih.gov/grants/guide/notice-files/not99-124.html. Phenotypic data from
the DCCT may be obtained by contacting the National Technical Information Service
(NTIS), 5285 Port Royal Road, Springfield, VA 22161, phone 888-584-8332.
Last updated: 7/27/2005
|